SK Biopharm buys license for epilepsy drug candidate from U.S. firm
--------------------------------------------------------------------
Source: South Korea
Published: 2026-08-26 13:08 UTC+10:00
Section: General
Factuality Score: 100
Opinion Category: Neutral
Topics: Health, Asia, South Korea, Elections, Drugs, Asia Pacific
--------------------------------------------------------------------
Snippet:
SEOUL, Aug. 26 (Yonhap) -- SK Biopharmaceuticals Co., a pharmaceutical affiliate of South Korea's SK Group, said in a regulatory filing Wednesday it has inked a "licensing-in" agreement worth around 1.9 trillion won (US$795 million) for an epilepsy drug candidate with a U.S. company.
--------------------------------------------------------------------